Trial Profile
A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Nemvaleukin-alfa (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Liver cancer; Lymphoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ARTISTRY-2
- Sponsors Alkermes; Mural Oncology
- 13 Sep 2023 Status changed from active, no longer recruiting to completed.
- 10 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 May 2023.
- 10 Apr 2023 This trial has been completed in Netherlands (End Date: 01 Mar 2023), according to European Clinical Trials Database record.